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CASE REPORT
Inflammatory Myofibroblastic Tumor of the Left Main
Stem Bronchus
Salvatore Privitera, MSc, MD,* David M. Hwang, PhD, MD,† and Gail E. Darling, MD*
Inflammatory myofibroblastic tumor (IMT) (pseudotumor) is a rare
solid tumor that most commonly affects the lung. Its unknown
etiology and cellular variability have resulted in inconsistent naming
of this lesion. Treatment modalities have varied, but complete
surgical resection seems to be most appropriate. We describe a
28-year-old woman with a near-obstructing IMT of the left main
stem bronchus (LMB) treated with bronchial sleeve resection.
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IMT is a rare mesenchymal proliferation with unpredictablebiological behavior that most often affects children and
young adults. Inconsistent nomenclature has been used to
describe this likely benign lesion because of its cellular
variability (including plasma cells and lipid-laden mononu-
clear [foam] cells). Descriptors include inflammatory pseudo-
tumor, plasma cell granuloma, fibrous histiocytoma, fibrox-
anthoma, xanthogranuloma, and inflammatory fibrosarcoma.1
IMT most frequently occurs in the lung, but its etiology
remains unclear. Although little is known about its natural
history, it tends to be locally invasive and, hence, recurrent.
Frozen section diagnosis is difficult, especially differentiating
between lymphoma and other malignant processes. We de-
scribe a case of primary IMT originating in the LMB.
Clinical Scenario
A 28-year-old Philippine woman who had been living
in Canada for almost 20 years was initially diagnosed with
bronchial asthma at age 18 years, when she presented with
wheezing and dyspnea. She experienced two separate epi-
sodes of pneumonia and subsequent persistent cough in the
year before referral to our center. This led to further investi-
gation. Other than her diagnosis of asthma, she was healthy,
with no history of gastroesophageal reflux, no occupational or
environmental exposures, and was a lifelong non-smoker.
Some symptom relief was provided by combinations of
salmeterol xinafoate-fluticasone propionate, montelukast so-
dium, salbutamol sulfate, and ipratropium bromide; however,
oral glucocorticoids were never used.
Pulmonary function tests revealed reduced vital capac-
ity to 1.54 L (57% predicted) with a restrictive pattern. A
methacholine challenge test was negative. A computed to-
mography scan of the chest revealed volume loss of the left
hemithorax and an endobronchial soft tissue density within
the LMB measuring 11  8 mm in size (Figure 1). Mild
paraseptal emphysema in the left upper lobe with minor linear
and reticular densities was noted subpleurally. The left lower
lobe was normal. Subsequent bronchoscopy revealed a near-
obstructing polypoid lesion in the LMB initially suspicious
for a carcinoid tumor; however, no pathology was available.
We used computed tomography to confirm complete patency
of the left upper- and lower-lobe bronchi.
In the operating room, flexible bronchoscopy revealed a
mass in the LMB approximately 2 cm from the tracheal
carina that did not appear to breach the mucosa. There was
sufficient bronchus distal to the lesion to permit resection
with re-anastomosis. After re-intubation with a double-lumen
endotracheal tube, a standard left postero-lateral thoracotomy
was performed. The mass was palpable in the LMB, and no
other masses were noted in the lung parenchyma. A LMB
sleeve resection with end-to-end anastomosis was performed,
allowing for preservation of the left lung. Frozen section
analysis indicated a spindle cell neoplasm with clear margins.
Final pathology revealed an IMT with negative mar-
gins. Station 7, 9, and 10L lymph nodes were all negative.
The overlying bronchial mucosa was near-normal in appear-
ance with no evidence of ulceration (Figure 2). Histologi-
cally, the tumor showed a heterogeneous mix of spindle cells
(mostly myofibroblastic), histiocytes, plasma cells, lympho-
cytes, and eosinophils (Figure 3). Some spindle cells exhib-
ited nuclear atypia but very few mitotic figures. There was no
necrosis, and p53 nuclear staining was negative. Immunohis-
tochemistry for cytokeratins (AE1/AE3, LMWK, HMWK)
was negative. Vimentin staining was strongly positive, par-
ticularly within spindle cells. The spindle cells did not stain
with desmin or smooth muscle actin. The histiocytic cells
stained with CD68 and chymotrypsin. S100 and CD34 were
negative.
Postoperatively, the patient made an uncomplicated
recovery. She continues to be asymptomatic and, at 1-year
follow-up bronchoscopy, remains free of recurrent disease.
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DISCUSSION
IMTs are rare lesions with a reported incidence of
0.04% to 1% of all tumors of the lung and no sexual
predominance.2 They are most commonly solitary and pe-
ripheral. Endobronchial IMT has an incidence of approxi-
mately 12%.3 Approximately 60% of these lesions occur in
patients younger than 30 years, whereas it is the most com-
mon primary tumor-like lesion in children younger than 16
years.4
IMTs may be asymptomatic because of their slow
growth and peripheral tendency, but endobronchial and larg-
er/invasive parenchymal lesions (with very rare rapid growth)
may cause symptoms of cough, wheeze, dyspnea, and/or
hemoptysis. Peripheral lesions tend to invade pleura, whereas
central lesions more often invade hilar structures. The differ-
ential diagnosis of IMT is broad because of its cellular
heterogeneity and includes lymphoma, lymphoid hyperplasia,
plasmacytoma, sarcomatoid carcinoma of the lung, sclerosing
hemangioma, malignant fibrous histiocytoma, and other sar-
comas.2 A history of acute respiratory illness, occurring in
one third of patients, suggests that the process represents a
stage in the resolution of acute pneumonia, although success-
ful culture of an organism is unusual.3 Other clinical features
may include clubbing, hypochromic microcytic anemia, in-
creased immunoglobulins, increased erythrocyte sedimenta-
tion rate, and increased thrombocyte count. Computed to-
mography scan of the chest usually shows a circumscribed
calcified mass.5
The nature of these lesions is controversial and may
represent either an immunologic/inflammatory response to an
infectious or noninfectious intervention or insult, or a low
grade mesenchymal neoplasia. Clonal cytogenetic changes in
one report of IMT suggest this may be a true neoplasm.6
Depending on the predominant cell types, IMT can be di-
vided into three groups: organizing pneumonia type with
predominant fibroblast-like spindle cells, fibrous histiocy-
toma type, and lymphoplasmacytic type.3 Endobronchial
growth is more often seen in the fibrous histiocytoma type.4
Histologically, spindle-shaped mesenchymal cells (mostly
myofibroblasts) and inflammatory cells (mostly plasma cells)
confirm the diagnosis. Immunohistochemical staining for
vimentin and smooth muscle actin is usually positive with
consistent ultrastructural features. The spindle cells often
have low cellular atypia and no mitotic activity. Inflammatory
cells typically show no cellular atypia and no monoclonal
proliferation.2
Although IMTs are rare and not well understood, the
accepted treatment is complete surgical resection with clear
margins (R0).1,5 Surgical removal usually accomplishes both
diagnosis and treatment. Preoperative procedures to diagnose
FIGURE 1. Computed tomography scan of the chest show-
ing a lobulated soft tissue density (nodule) in the left main
stem bronchus. The arrow indicates the nodule).
FIGURE 2. Tumor arising from and entrapping normal
structures in the bronchial mucosa, with partial luminal ob-
struction. Original magnification, 16 (A) and 50 (B).
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IMT can cause confusion with other potential diagnoses.1 At
the time of surgery, local resection is appropriate, and frozen
section analysis should be performed to ensure clear margins.
Frozen section diagnosis may be indeterminate but will usu-
ally rule out malignancy.1 Lobectomy may be required to
ensure complete resection for large tumors. Pneumonectomy
should only be considered with pathologic confirmation by
incisional biopsy. Our case involved bronchial sleeve resec-
tion for complete removal of the lesion and is supported by a
similar report involving the right tracheo-bronchial angle.7
Other reports describe bronchotomy8 or laser bronchoscopy.9
Neither report, however, discussed follow-up or complete
resection of disease. Given the incidence of recurrence with
incomplete resection (three of five patients in the study by
Cerfolio et al.1), ensuring complete removal with negative
margins is essential, resulting in an overall survival of 91%.1
Other reports have indicated that radiotherapy,1 corticoste-
roids,10 and COX-2 inhibitors11 may be useful, especially for
inoperable tumors, and may lead to decreased size or com-
plete regression of the lesion. Spontaneous regression is very
rare.1
We report the treatment of a LMB IMT via bronchial
sleeve resection. This approach permitted a complete resec-
tion with preservation of pulmonary parenchyma.
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FIGURE 3. The tumor is composed of a heterogeneous mix
of myofibroblastic spindle cells (long arrows), foamy histio-
cytes (short arrows), lymphocytes, plasma cells (dashed ar-
rows), eosinophils, and occasional multinucleated giant cells.
Original magnification, 200.
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